Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase NA 3Phase 3 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 1 2Phase 4 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Testicular Neoplasms 1Muscle Weakness 1Multiple Endocrine Neoplasia Type 1 1Motor Activity 1Metabolic Syndrome 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Testosterone × Clear all
NCT02873559 2024-05-29

PROGRESS

University Hospital, Gentofte, Copenhagen

Phase 2/3 Completed
192 enrolled
Endocrine

Motor Activity, Multiple Endocrine Neoplasia Type 1, Muscle Weakness

NCT02991209 2020-03-06

Einstein

Rigshospitalet, Denmark

Phase 2/3 Completed
69 enrolled
Genitourinary

Testicular Neoplasms, Metabolic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡